Indivi Secures CHF 15 Million Investment to Accelerate the Discovery of Treatment Response Biomarkers in Neuroscience Drug Development, Targeting Alzheimer’s Disease

S. Belashew

‹ Adaptive Cognitive Assessments with Dynamic Difficulty Adjustment to Improve Biomarker Responsiveness in Alzheimer’s Disease

Smartphone-based digital assessments in the LUMA trial of BIIB122/DNL151 for early-stage Parkinson’s disease ›